Search
Scienture Holdings Inc
SCNXAdd to Watchlist
0.344USD
-0.012-3.45%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
13.98MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-3.45%
5 Days
-4.50%
1 Month
-9.47%
6 Months
-33.92%
Year to Date
-32.55%
1 Year
-76.28%
Key Figures
0.360Open
0.373High
277.64KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.68%Turnover Ratio
0.356Prev. Close
0.333Low
51.70KTurnover
1.54P/E Static
0.21P/B
0.00%Div Yield TTM
-44.76%ROA
2.60052wk High
2.36Volume Ratio
9.07MNet Profit
40.63MShares
-2.4635EPS TTM
3.25Beta
-56.56%ROE
0.23852wk Low
11.23%Amplitude
95.61%Gross Margin
13.98MMarket Cap
-0.46Reward/Risk
13.47%Risk Rate
TradingKey Stock Score of Scienture Holdings Inc
Currency: USD Updated: 2026-07-02Key Insights
Scienture Holdings Inc's fundamentals are relatively very healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 109 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 1.50.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Scienture Holdings Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Scienture Holdings Inc Highlights
StrengthsRisks
Scienture Holdings, Inc., through its wholly owned subsidiary, Scienture, LLC, is a specialty pharmaceutical company focused on providing enhanced value to patients, physicians and caregivers by offering specialty products to satisfy unmet market needs. Scienture, LLC is focused on developing and commercializing products for the treatment of central nervous system and cardiovascular diseases. Scienture LLC is developing a range of product candidates, including new potential treatments for hypertension, migraine, pain and thrombosis and other related disorders. The Company's product candidates include SCN- 102 (hypertension), SCN- 104 (CNS-Pain), SCN- 106 (Cardiovascular) and SCN- 107 (Pain). SCN-102 is an oral liquid formulation of losartan potassium in development for the treatment of hypertension. SCN-104 is a multi-dose pen-based delivery system for self-injection and increased patient convenience, which is in development for the acute treatment of migraine headaches.
Growing
The company is in a growing phase, with the latest annual income totaling USD 431.61K.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 431.61K.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Fairly Valued
The company’s latest PE is -0.14, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 2.00M shares, increasing 12.65% quarter-over-quarter.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
1.500
Target Price
+320.99%
Upside Space
Scienture Holdings Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Scienture Holdings Inc Info
Scienture Holdings, Inc., through its wholly owned subsidiary, Scienture, LLC, is a specialty pharmaceutical company focused on providing enhanced value to patients, physicians and caregivers by offering specialty products to satisfy unmet market needs. Scienture, LLC is focused on developing and commercializing products for the treatment of central nervous system and cardiovascular diseases. Scienture LLC is developing a range of product candidates, including new potential treatments for hypertension, migraine, pain and thrombosis and other related disorders. The Company's product candidates include SCN- 102 (hypertension), SCN- 104 (CNS-Pain), SCN- 106 (Cardiovascular) and SCN- 107 (Pain). SCN-102 is an oral liquid formulation of losartan potassium in development for the treatment of hypertension. SCN-104 is a multi-dose pen-based delivery system for self-injection and increased patient convenience, which is in development for the acute treatment of migraine headaches.
Ticker SymbolSCNX
CompanyScienture Holdings Inc
CEOHariharan (Shankar)
Website
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Scienture Holdings Inc (SCNX)?
The current price of Scienture Holdings Inc (SCNX) is 0.34.
What is the symbol of Scienture Holdings Inc?
The ticker symbol of Scienture Holdings Inc is SCNX.
What is the 52-week high of Scienture Holdings Inc?
The 52-week high of Scienture Holdings Inc is 2.60.
What is the 52-week low of Scienture Holdings Inc?
The 52-week low of Scienture Holdings Inc is 0.24.
What is the market capitalization of Scienture Holdings Inc?
The market capitalization of Scienture Holdings Inc is 13.98M.
Is Scienture Holdings Inc (SCNX) currently rated as Buy, Hold, or Sell?
According to analysts, Scienture Holdings Inc (SCNX) has an overall rating of Buy, with a price target of 1.50.
What is the Earnings Per Share (EPS TTM) of Scienture Holdings Inc (SCNX)?
The Earnings Per Share (EPS TTM) of Scienture Holdings Inc (SCNX) is -2.70.